Ginkgo Bioworks Holdings, Inc. Class A DNA 深 沪
已收盘 01-30 16:00:00 美东时间
8.97
-0.340
-3.65%
华盛通- 最 高9.41
- 今 开9.02
- 成交量 76.88万股
- 最 低 8.97
- 昨 收 9.31
- 总市值 5.31亿
- 52周最高 17.58
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 5.00
- 委 比 70.71%
- 总股本 5919.98万
- 历史最高 634.56
- 量 比 1.23
- 振 幅 4.73%
- 历史最低 5.00
- 每 手 1
- 风险率 2.56%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
TD Cowen Maintains Buy on Ginkgo Bioworks Holdings, Lowers Price Target to $12
TD Cowen analyst Brendan Smith maintains Ginkgo Bioworks Holdings (NYSE:DNA) with a Buy and lowers the price target from $14 to $12.
01-09 02:42
Ginkgo Bioworks shares are trading higher after the company announced its partnership with Carnegie-Mellon University for an award by the Advanced Research Projects Agency for Health for its POSEIDON program.
Ginkgo Bioworks shares are trading higher after the company announced its partn...
2025-12-23 02:53
Ginkgo Bioworks Awarded 4-Yr, Up To $47M Contract By EMSL To Co-Design, Build, And Integrate High‑Throughput Automated Phenotyping Platform In Support Of M2PC
Ginkgo Bioworks (NYSE:DNA) today announced it has been awarded by the Environmental Molecular Sciences Laboratory (EMSL) at Pacific Northwest National Laboratory (PNNL) a four-year, up to $47M contract to co-design,
2025-12-05 21:42
Ginkgo Bioworks Selected by PNNL to Deliver a Modular, High‑Throughput Phenotyping Platform for DOE's M2PC
BOSTON, Dec. 5, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced it has been awarded by the Environmental Molecular Sciences Laboratory (EMSL) at Pacific Northwest National L...
2025-12-05 21:33
Ginkgo Bioworks Holdings Q3 EPS $(1.45) Misses $(1.24) Estimate, Sales $38.837M Miss $38.850M Estimate
Ginkgo Bioworks Holdings (NYSE:DNA) reported quarterly losses of $(1.45) per share which missed the analyst consensus estimate of $(1.24) by 16.94 percent. This is a 34.26 percent decrease over losses of $(1.08) per
2025-11-07 05:14
Ginkgo Bioworks Awarded Up To $22.2M Contract From Biopharmaceutical Manufacturing Preparedness Consortium To Develop Innovations To Lower Costs Of Local Biomanufacturing Of Monoclonal Antibodies
Ginkgo Bioworks (NYSE: DNA) announced today that it has been awarded a contract through the Biomedical Advanced Research and Development Authority's (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium
2025-11-03 21:13
